drugset / Trial / NCT00266058

Drug Interaction Study Between Antimalarial and Anti-HIV Medications

NCT00266058

Phase 1 Completed 33 enrolled University of California, San Francisco
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to find out whether taking certain anti-HIV medicines with certain antimalarial medicines affects the amount of the medicines in the blood. The study medicines that will be used are artemether/lumefantrine (antimalarial medication) and lopinavir/ritonavir or efavirenz (anti-HIV medications). Artemether/lumefantrine is not approved by the United States Food and Drug Administration (FDA) but is recommended as standard of care medical treatment for malaria in Africa and Asia. Lopinavir/ritonavir and efavirenz are approved by the FDA. Artemether/lumefantrine and lopinavir/ritonavir or efavirenz may need to be used together to treat children in Africa and Asia. We seek to learn about whether or not the use of these medicines together results in a change in blood levels of any of these medicines. The information obtained from this study will help doctors to provide a better treatment to children and adults with malaria and HIV.

Timeline

Start
2005-12
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether Small molecule 80 mg
Comparator Efavirenz Other / unclassified 600 mg
Comparator Lopinavir Other / unclassified 400 mg
Comparator Ritonavir Other / unclassified 100 mg
Comparator lumefantrine Small molecule 480 mg